Aptose Biosciences

Corporate Headquarters
251 Consumers Road
Suite 1105
Toronto
Ontario
M2J 4R3
Canada

Show jobs for this employer

102 articles with Aptose Biosciences

  • Aptose Biosciences Inc. is releasing highlights from a corporate update event being held today, Friday, June 11, 2021, at 8:00 a.m. ET.

  • Aptose Biosciences Inc., a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, announced the voting results from the Company’s annual and special meeting of shareholders held today, June 1, 2021.

  • Clinical Updates for Luxeptinib in AML & B-cell Cancers and for APTO-253 in AML & MDS Poster Presentations for CG-806 and APTO-253 are Scheduled for June 11th at  EHA2021 Virtual Congress

  • - Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that the Aptose management team will participate in upcoming investor conferences: 2021 RBC Capital Markets Global Healthcare Virtual Conference Date:       Wednesday, May 19, 2021 Time:   11:30 AM – 11:55 AM EDT

  • Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced financial results for the three months ended March 31, 2021 and provided a corporate update.

  • Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will report financial results for the quarter ended March 31, 2021, and provide a corporate update on Tuesday, May 4, 2021, after the close of the market. Conference Call & Webcast:   Date: Tuesday, May 4, 2021 Time: 4:30 PM ET

  • Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference

  • Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced financial results for the year and three months ended December 31, 2020 and a corporate update.

  • Aptose Biosciences Inc. announced the appointment of two key members to its management team to support the company’s expanding clinical CMC and regulatory functions: George P. Melko, Pharm.D., joins Aptose as Vice President, Regulatory Affairs; and Robert B. Killion Jr., Ph.D. has been named Vice President, CMC.

  • Aptose Biosciences Inc., a clinical stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the year and quarter ended December 31, 2020, on Tuesday, March 23, 2021 after the close of the market.

  • Aptose Biosciences Inc. released highlights from a corporate update event held on Sunday, December 6th, in conjunction with participation at the 2020 American Society of Hematology Annual Meeting.

  • Poster Presentations for CG-806 and APTO-253 are scheduled for December 5th and 6th at 2020 ASH Annual Meeting and Exposition

  • Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced financial results and a corporate update for the three months ended September 30, 2020.

  • Aptose Biosciences Inc. (“Aptose”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that early clinical data, along with certain preclinical data, for CG-806, an oral, first-in-class FLT3 and BTK cluster selective kinase inhibitor, and early clinical data for APTO-253, a first-in-class small molecule MYC inhibitor, will be prese

  • Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, will release its financial results for the quarter ended September 30, 2020 on Tuesday, November 10, 2020, after the close of the market.

  • Aptose Biosciences Inc. announced dosing of the first patient with acute myeloid leukemia in a Phase 1 a/b clinical study with CG-806, the company’s oral kinase inhibitor that potently inhibits the wildtype and mutant forms of FLT3 and BTK, and suppresses select clusters of kinases that drive oncogenic signaling pathways.

  • Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will participate at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit: Oppenheimer Fall Healthcare Life Sciences & Medtech

  • Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, and the Aptose management team will participate at the upcoming conferences in September 2020: H. C. Wainwright 22nd Annual Global Investment Conference Date: Monday,

  • Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer; Gregory K. Chow, Executive Vice President and Chief Financial Officer; and Joti Marango, M.D., Ph.D, Senior Vice President and Chief Business Officer, will participate in the Cana

  • Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, today announced financial results and corporate update for the three months ended June 30, 2020.